Introduction
Bone metastasis occurs in approximately 65 -75% of patients with advanced breast carcinoma 1, 2 and is generally incurable, resulting in intense pain, pathological fractures, hypocalcaemia, nerve compression and death. 3, 4 The aetiology of bone metastasis is complicated and remains unclear, but is likely to involve both environmental and genetic factors. Although breast cancer is the leading cause of cancer-related deaths in women worldwide, 5 breast cancer-associated mortality is declining, mainly due to an increased understanding of the molecular mechanisms of tumour development, together with advances in diagnostic technology, such as mammographic screening. 6, 7 Current detection methods cannot accurately diagnose bone metastases in all patients with breast cancer, however. 8, 9 The low sensitivity of the tumour markers cancer antigen 15-3 and carcinoembryonic antigen has limited their use in the detection of breast cancer. 10 In addition, prognostic markers of primary breast carcinoma (such as plasminogen activator inhibitor 1, urokinasetype plasminogen activator and ERBB2, which encodes human epidermal growth factor a F-L Zhao and G-D Hu contributed equally to this work.
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MicroRNA-10b in bone metastatic breast cancer receptor 2 [HER-2]) have a limited ability to predict eventual metastatic progression. 11 Urgent improvements in the detection of bone metastases from primary breast tumours are required in order to reduce mortality further and also to reduce treatment costs.
MicroRNAs (miRs) are small, noncoding RNA molecules that regulate mRNA stability and transcription in a wide range of physiological and pathological processes including apoptosis, cell differentiation and proliferation, and tumour invasion and metastasis. 12 -16 Several hundred miRs have been identified in humans. 17 MiR-10b is considered to be closely correlated with metastatic behaviour 18 and has been shown to be abnormally expressed in breast cancer metastasis, 19, 20 possibly representing a novel therapeutic target. Abnormal miR-10b expression occurs in the progression of many tumour types including neurofibromatosis, 21 nasopharyngeal carcinoma 22 and pancreatic cancer, 23 and in oesophageal cancer cell lines. 24 The aim of the current study was to investigate the involvement of miR-10b in the development of bone metastasis arising from primary breast carcinoma. Serum concentrations of miR-10b in women with different clinical stages of breast cancerwith or without bone metastases -were compared with concentrations in healthy control subjects.
Patients and methods

STUDY POPULATION
This prospective case-control study recruited consecutive patients with histologically confirmed primary breast cancer attending the Department of Orthopaedics, the Beijing People Hospital, Beijing, China, between 1 January 2009 and 1 January 2011. Healthy age-matched female control subjects were recruited from those attending the Department of Orthopaedics for routine health screening. There were no other inclusion or exclusion criteria.
Demographic and clinicopathological details of patients were obtained from the Medical Records Department of the Beijing People Hospital. These included age, diameter of the primary tumour, presence of bone metastasis, and oestrogen receptor, progesterone receptor and HER-2 status. Patients were classified according to the International Union Against Cancer tumour-node-metastasis classification system for secondary breast cancer tumours. 25 Bone metastasis was diagnosed and confirmed in patients with breast cancer, according to previously described methods. 9, 26, 27 This study was approved by the Ethics Committee of the Beijing People Hospital. Written informed consent was obtained from all participants.
SERUM SAMPLES AND PREPARATION OF TOTAL RNA
Blood was collected in sterile tubes, centrifuged at 1300 g for 10 min at room temperature and stored at -80°C until processing. Serum was collected from all study participants for measurement of miR, which is known to be abundant in human serum. 28 Total RNA was extracted from 100 ml of serum using TRIzol ® reagent (Invitrogen Corp., Carlsbad, CA, USA), according to the manufacturer's instructions.
REVERSE TRANSCRIPTION OF MIR
Each RNA sample (10 ng RNA in a volume of 10 µl) was mixed with 3 µl of 5 µM stem-loop reverse transcription (RT) primers for miR10b and miR-16 (Invitrogen Biotechnology Co., Ltd, Shanghai, China; Table 1 ), designed 
REAL-TIME PCR ANALYSIS OF MIR-10B
Detection of miR-10b and miR-16 was by real-time PCR using sequence-specific and universal primers (Applied Biosystems, Foster City, CA, USA; Table 2 ). Each cDNA sample (1.6 µl) was mixed with 1 µl of each PCR primer (0.2 µM each specific primer; 0.5 µM each universal primer), 10 µl of SYBR ® Green PCR Master Mix (Applied Biosystems) and 6.4 µl diethylpyrocarbonate-treated water. The PCR cycling programme involved preliminary denaturation at 95°C for 10 min, followed by 40 cycles of denaturation at 95°C for 15 s, annealing at 60°C for 1 min and elongation at 4°C for 60 s in a 7500 Fast Real-Time PCR System (Applied Biosystems). A template-free reaction was used as a negative control. The threshold cycle (C T ) was defined as the cycle number at which the fluorescence passed the fixed threshold. MiR expression levels were calculated by relative quantification using the Applied Biosystems 7500 Fast Real-Time PCR System SDS software, version 1.2 (Applied Biosystems). The fold change of expression of miR-10b concentrations was determined using the 2 −∆∆CT method, as previously described. 31, 32 MiR-10b expression was defined as positive when ≥ 2-fold changes were observed. 
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MicroRNA-10b in bone metastatic breast cancer STATISTICAL ANALYSES
Data were expressed as mean ± SD and were evaluated by distribution-free tests and the Wilcoxon signed-rank test. Receiver operating characteristic (ROC) curve analysis was used to calculate the miR-10b cut-off value and assess its sensitivity and specificity in the diagnosis of bone metastatic breast cancer. All tests were twotailed. Statistical analyses were performed using the SPSS ® statistical package, version 16.0 (SPSS Inc., Chicago, IL, USA) for Windows ® . A P-value < 0.05 was considered statistically significant.
Results
The study recruited 122 women with breast cancer (median age 52 years; range 26 -77 years) and 59 healthy age-matched female control subjects (median age 50 years; range 28 -72 years). Of the 122 patients with breast cancer, 22 (18.0%) had confirmed bone metastases.
Real-time RT-PCR successfully amplified miR-16 and miR-10b from serum samples (Fig. 1A) . The melting curves of miR-10b and miR-16 were sharply defined with a narrow peak, indicating the generation of pure, homogeneous PCR products (Fig. 1B) . MiR10b was present at higher concentrations in patients with breast cancer compared with control subjects. Although miR-10b concentrations were not significantly higher in patients with stages I, II and III breast cancer than in control subjects, the level of miR-10b was significantly higher in patients with bone metastatic breast cancer (stage IV) compared with patients without bone metastases (stages I, II or III) and healthy control subjects (P = 0.009, P = 0.026, P = 0.029 and P = 0.004, respectively) (Fig. 2A) ; ratios were 1.93, 2.83, 3.11 and 1.69, respectively. ROC analysis determined that a cut-off value of 0.5498 for miR-10b was optimal in the differentiation between breast cancer patients with or without bone metastases, with a sensitivity of 64.8%, a specificity of 69.5% and an area under the curve of 0.769 (Fig. 2B) .
Discussion
The present study measured serum miR-10b in healthy control subjects and patients with primary breast cancer, with or without bone metastases. To our knowledge, this is the first report indicating a role for miR-10b in the development of breast cancer metastasis.
This study found increased serum concentrations of miR-10b in patients with breast cancer (with or without bone metastases) compared with healthy control subjects. MiR-10b has been shown to be abnormally expressed in several tumour types including glioma, 33 pancreatic adenocarcinoma 34 and glioblastoma. 35 The current findings, together with previous studies, suggest a role for miR-10b in cancer and metastatic behaviour. Cancer metastasis is associated with a number of changes in proteins and gene expression, 36 further corroborating the current miR-10b findings. The role of miR-10b in bone metastatic breast cancer is unknown. Serum miR-10b concentrations were significantly higher in patients with bone metastases than in those free from such metastases in the present study, although no other type of metastasis was examined. This finding is in accordance with studies that have reported elevated miR-10b concentrations in breast cancer metastasis. 19, 37 MiR-10b concentrations correlate with tumour grade and invasiveness in human gliomas, 33 and the levels at the growing edge of the tumour in advanced-stage breast cancer patients may predict future metastatic recurrence. 38 Increased serum miR-10b concentrations were associated with bone metastases in the present study, suggesting that the overexpression of miR-10b may play The results of the present study suggest that miR-10b may be worthy of further evaluation as a prognostic marker in breast cancer, although its molecular mechanism requires further investigation.
In conclusion, this study found significantly higher concentrations of serum miR-10b in patients with bone metastatic breast cancer compared with patients without such metastases. The concentrations of miR-10b increased in line with worsening clinical stage. These results implicate miR10b in the development of breast cancer bone metastasis, and may represent a new therapeutic target.
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